Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 5.493
Filter
1.
PLoS Negl Trop Dis ; 18(8): e0012405, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39172763

ABSTRACT

BACKGROUND: In clinical practice guidelines, there is no consensus about the medications that should be initially offered to patients with brucellosis. To provide informative evidence, we compared and ranked brucellosis medications based on their efficacy and safety. METHODS: For this systematic review and network meta-analysis, we searched 4 English databases and 3 Chinese databases, from the date of database inception to December 13, 2023. We included randomized controlled trials (RCTs) involving children and adolescents with brucellosis, comparing different antibiotic regimens. We excluded studies explicitly targeting patients with spondylitis brucellosis, endocarditis brucellosis, and neuro-brucellosis. The primary outcomes were overall failure (efficacy) and side effects (safety). Secondary outcomes were relapse and therapeutic failure. Pairwise meta-analysis was first examined. Data were analyzed using random effects network meta-analysis, with subgroup and sensitivity analyses performed. The Confidence in Network Meta-Analysis (CINeMA) framework was used to assess the certainty of evidence. The protocol was preregistered in PROSPERO (CRD42023491331). RESULTS: Of the 11,747 records identified through the database search, 43 RCTs were included in the network meta-analysis. Compared with standard therapy (Doxycycline + Rifampicin), Rifampicin + Tetracyclines (RR 4.96; 95% CI 1.47 to 16.70; very low certainty of evidence), Doxycycline + TMP/SMX (RR 0.18; 95% CI 0.06 to 0.52; low certainty of evidence), Doxycycline + Quinolones (RR 0.27; 95% CI 0.11 to 0.71; low certainty of evidence), Streptomycin + Tetracyclines (RR 0.04; 95% CI 0.01 to 0.16; low certainty of evidence), and Single (RR 0.05; 95% CI 0.02 to 0.16; moderate certainty of evidence) were less efficacious. Doxycycline + Gentamicin ranked the best in efficacy (SUCRA values: 0.94), the second is Triple (SUCRA values: 0.87), and the third is Doxycycline + Streptomycin (SUCRA values: 0.78). CONCLUSIONS: Brucellosis medications differ in efficacy and safety. Doxycycline + Gentamicin, Triple, and Doxycycline + Streptomycin have superior efficacy and safety. Treatment of brucellosis should strike a balance between efficacy, safety, and cost.


Subject(s)
Anti-Bacterial Agents , Brucellosis , Network Meta-Analysis , Randomized Controlled Trials as Topic , Brucellosis/drug therapy , Humans , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Adolescent , Child , Streptomycin/therapeutic use , Rifampin/therapeutic use , Drug Therapy, Combination
2.
Medicine (Baltimore) ; 103(32): e39268, 2024 Aug 09.
Article in English | MEDLINE | ID: mdl-39121308

ABSTRACT

RATIONALE: The geographic spread of Japanese spotted fever (JSF) in China is gradually expanding, particularly in regions where severe fever with thrombocytopenia syndrome (SFTS) is highly prevalent, with both diseases sharing similarities in epidemiology and clinical presentation. The microbiological diagnosis of JSF is challenging, compounded by low awareness among healthcare professionals in newly affected areas. Moreover, primary healthcare facilities without polymerase chain reaction (PCR) testing capabilities for SFTS often misdiagnose JSF as SFTS. PATIENT CONCERNS: All 3 patients had a history of working in the fields, with cold like symptoms in the early fever stages, but the fever did not improve after a few days. The accompanying symptoms were also very different. Physical examination revealed enlarged lymph nodes, different forms of rash, with or without eschar. Laboratory tests showed thrombocytopenia, eosinophilia, elevated lactate dehydrogenase, and transaminase, with 1 patient experiencing renal damage. It is worth noting that these 3 patients reside in an area where SFTS is endemic, and there have been no prior reports of JSF. They exhibited clinical symptoms and laboratory test results closely resembling those of SFTS. Therefore, they were initially misdiagnosed with SFTS in their local hospitals. DIAGNOSES: The 3 patients who arrived at our hospital 7 days after symptom onset and were subsequently diagnosed with JSF by metagenomic next-generation sequencing (mNGS). INTERVENTIONS: Doxycycline treatment for 1 week. OUTCOMES: The patients' symptoms quickly improved with no side effects, and the results of laboratory tests went back to normal. LESSONS: By comparing the clinical characteristics of JSF patients and SFTS patients comprehensively, we found that APTT and procalcitonin levels may be valuable in assisting in the identification of SFTS and JSF. In all areas where tick-borne diseases are endemic, include SFTS-epidemic areas, we recommend using the Weil-Felix test to screen for potential rickettsiosis in patients presenting with fever and thrombocytopenia with or without rash in primary healthcare settings, as well as simultaneous testing for the SFTS virus and spotted fever group rickettsioses sequence. Additionally, mNGS sequencing should be used to confirm the diagnosis and provide information for epidemiological investigations in patients who are suspected of having spotted fever group rickettsiosis.


Subject(s)
Phlebovirus , Humans , Male , Phlebovirus/isolation & purification , Middle Aged , Severe Fever with Thrombocytopenia Syndrome/diagnosis , Severe Fever with Thrombocytopenia Syndrome/epidemiology , China/epidemiology , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/epidemiology , Female , Adult , Doxycycline/therapeutic use , Endemic Diseases , Diagnostic Errors , Anti-Bacterial Agents/therapeutic use
3.
J Microbiol Methods ; 224: 107009, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39098402

ABSTRACT

The present investigation aimed to quantitatively assess the level of parasitemia in dogs using qPCR.The dogs selected for this study were infected with the haemoprotozoan parasite Babesia gibsoni. In the study, dogs diagnosed with babesiosis were divided into two groups (n = 12) and subjected to distinct treatment strategies. The first group received clindamycin-metronidazole-doxycycline (CMD) therapy, while the second group was treated with a combination of buparvaquone-azithromycin (BPV-AZM). The level of parasitemia in the infected dogs was determined using an absolute quantification-based qPCR method. This assessment was conducted both prior to initiating the treatment and on the 10th day following the commencement of the treatment protocols. On the tenth day after the initiation of treatment, the CMD group exhibited a lower level of parasitemia in comparison to the BPV-AZM group. In the CMD treated groups, the mean parasitemia decreased from 4.9E + 06 to 3.4E + 06, indicating a reduction in parasitic load. Conversely, in the BPV-AZM treatment groups, the mean parasitemia increased from 1.62E + 06 to 2.87E + 06, suggesting an increase in parasitic load. On the 10th day, the CMD-treated group demonstrated a statistically significant decline in the level of parasitemia, with a P-value of ≤0.001. This indicates a strong and significant reduction in parasitic load following the CMD treatment. Therefore, the absolute quantification-based qPCR method could effectively assess the initial treatment response by measuring the level of parasitemia.


Subject(s)
Babesia , Babesiosis , Clindamycin , Dog Diseases , Parasite Load , Parasitemia , Real-Time Polymerase Chain Reaction , Animals , Dogs , Dog Diseases/parasitology , Dog Diseases/diagnosis , Dog Diseases/drug therapy , Real-Time Polymerase Chain Reaction/methods , Babesia/genetics , Babesia/isolation & purification , Parasitemia/parasitology , Parasitemia/veterinary , Babesiosis/parasitology , Babesiosis/diagnosis , Clindamycin/therapeutic use , Parasite Load/methods , Doxycycline/therapeutic use , Azithromycin/therapeutic use , Metronidazole/therapeutic use , Antiprotozoal Agents/therapeutic use , Naphthoquinones
4.
Sci Rep ; 14(1): 19037, 2024 08 16.
Article in English | MEDLINE | ID: mdl-39152180

ABSTRACT

Brucellosis is a difficult to treat infection that requires antibiotic combinations administered over several weeks for clearance of infection and relapse prevention. This systematic review summarizes current evidence for antibiotic treatment of human brucellosis. PubMed, EMBASE, Scopus, CINAHL, Web of Science, and China Academic Journal databases were searched for prospective studies that had compared different antibiotic regimens for treating human brucellosis in the last 25 years. Thirty-four studies recruiting 4182 participants were eligible. Standard dual therapy with doxycycline + rifampicin had a higher risk of treatment failure compared to triple therapy which added streptomycin (RR: 1.98, 95% CI 1.17-3.35, p = 0.01) or levofloxacin (RR: 2.98, 95% CI 1.67-5.32, p = 0.0002), but a similar or lower risk compared to alternative dual antibiotic combinations (p > 0.05). The same combination had a higher risk of relapses compared to triple therapy which added streptomycin (RR: 22.12, 95% CI 3.48-140.52, p = 0.001), or levofloxacin (RR: 4.61, 95% CI 2.20-9.66, p < 0.0001), but a similar or lower risk compared to other dual antibiotic combinations (p > 0.05). Triple antibiotic therapy is more effective than standard dual therapy with rifampicin and doxycycline. However, the latter is also efficacious and suitable for uncomplicated disease.


Subject(s)
Anti-Bacterial Agents , Brucellosis , Humans , Anti-Bacterial Agents/therapeutic use , Brucellosis/drug therapy , Doxycycline/therapeutic use , Drug Therapy, Combination , Levofloxacin/therapeutic use , Rifampin/therapeutic use , Streptomycin/therapeutic use , Treatment Outcome
5.
PLoS Negl Trop Dis ; 18(8): e0012313, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39102427

ABSTRACT

Human granulocytotropic anaplasmosis (HGA) is a zoonotic tick-borne bacterial infection caused by Anaplasma phagocytophilum. While most cases are reported from North America, HGA has been recognized as an emerging disease in several regions of the world in recent decades. Most available data comes from case reports, case series and retrospective studies, while prospective studies and clinical trials are largely lacking. To obtain a clearer picture of the currently known epidemiologic distribution, clinical and paraclinical presentation, diagnostic aspects, complications, therapeutic aspects, and outcomes of HGA, we systematically reviewed the literature and analyzed and summarized the data. Cases of HGA are reported from all continents except from Antarctica. HGA primarily presents as an unspecific febrile illness (88.5% of the cases) often accompanied by thrombocytopenia (71.8% of the cases), abnormal liver injury tests (66.7% of the cases), and leukopenia (49.8% of the cases). Although we found complications reported in a total of 40.5% of the reviewed cases and severe and even life-threatening complications are not infrequent (e.g. acute renal failure 9.8%, multi organ failure 7.5%, ARDS 6.3%, a.o.), sequelae are rare (2.1% of the cases) and lethality is low (3.0% of the cases). Treatment with doxycycline shows a rapid response, with the fever subsiding in the majority of patients within one day of starting treatment. Unlike in human monocytotropic ehrlichiosis (HME), reports of opportunistic infections complicating HGA are rare. HGA during pregnancy does not appear to be associated with unfavorable outcomes. In addition, our analysis provides some evidence that HGA may differ in clinical aspects and laboratory characteristics in different regions of the world. Overall, the data analyzed indicates a non-negligible bias in reporting/publication, so a certain degree of caution is required when generalizing the data.


Subject(s)
Anaplasma phagocytophilum , Humans , Anaplasma phagocytophilum/isolation & purification , Anaplasmosis/epidemiology , Anaplasmosis/drug therapy , Anaplasmosis/microbiology , Anti-Bacterial Agents/therapeutic use , Female , Animals , Doxycycline/therapeutic use
6.
Viral Immunol ; 37(6): 298-307, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39096169

ABSTRACT

The COVID-19 pandemic response has been hindered by the absence of an efficient antiviral therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The reason why the previous preventative approach to COVID-19 solely through vaccines has failed could be a lack of understanding of how quickly the SARS-CoV-2 virus evolves. Given the absence of specific treatments for the virus, efforts have been underway to explore treatment options. Drug repurposing involves identifying new therapeutic uses for approved drugs, proving to be a time-saving strategy with minimal risk of failure. In this study, we report the successful use of a multidrug approach in patients with COVID-19. Successful administration of multidrug therapy, such as combinations of hydroxychloroquine and azithromycin, doxycycline and ivermectin, or ivermectin, doxycycline, and azithromycin, has been reported. Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl).


Subject(s)
Antiviral Agents , Azithromycin , COVID-19 Drug Treatment , COVID-19 , Drug Repositioning , Hydroxychloroquine , Ivermectin , Lopinavir , Ritonavir , SARS-CoV-2 , Humans , Antiviral Agents/therapeutic use , SARS-CoV-2/drug effects , Hydroxychloroquine/therapeutic use , Ivermectin/therapeutic use , Ritonavir/therapeutic use , Azithromycin/therapeutic use , Lopinavir/therapeutic use , Male , Drug Therapy, Combination , Doxycycline/therapeutic use , Drug Combinations , Middle Aged , Female , Antibodies, Monoclonal, Humanized/therapeutic use , Treatment Outcome , Aged , Pregnenediones/therapeutic use
8.
Praxis (Bern 1994) ; 113(6-7): 179-182, 2024 Jul.
Article in German | MEDLINE | ID: mdl-39166785

ABSTRACT

INTRODUCTION: A hunter with a history of oncology, flu-like symptoms and ring-shaped erythema was treated with doxycycline in an outpatient setting on suspicion of a tick-borne disease. After obtaining a positive Francisella tularensis serology, antibiotic treatment was continued for a total of 21 days, followed by freedom of symptoms and falling CRP, but without prompt serological follow-up. In contrast to the previously described tularemia cases in Switzerland, the article shows less pronounced local finding without palpable lymphadenopathy.


Subject(s)
Tularemia , Humans , Male , Tularemia/diagnosis , Tularemia/drug therapy , Diagnosis, Differential , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Erythema/etiology , Influenza, Human/diagnosis , Influenza, Human/complications , Francisella tularensis/isolation & purification , Middle Aged , Switzerland
9.
Lakartidningen ; 1212024 Aug 02.
Article in Swedish | MEDLINE | ID: mdl-39101261

ABSTRACT

STI prophylaxis using doxycycline is discussed internationally for persons at high risk of STIs (Doxy-PEP). Doxy-PEP would probably have limited effect on gonorrhoea due to resistance to tetracyclines. Doxy-PEP may reduce the incidence of chlamydia and syphilis, but would not reduce the number of complicated infections. Further studies are needed on the effects of intermittent antibiotic use on the microbiome or antibiotic resistance in general.


Subject(s)
Anti-Bacterial Agents , Chlamydia Infections , Doxycycline , Gonorrhea , Sexually Transmitted Diseases , Humans , Doxycycline/administration & dosage , Doxycycline/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Gonorrhea/drug therapy , Gonorrhea/prevention & control , Sexually Transmitted Diseases/prevention & control , Chlamydia Infections/prevention & control , Chlamydia Infections/drug therapy , Syphilis/drug therapy , Syphilis/prevention & control , Antibiotic Prophylaxis , Drug Resistance, Bacterial
10.
BMC Infect Dis ; 24(1): 766, 2024 Aug 01.
Article in English | MEDLINE | ID: mdl-39090536

ABSTRACT

BACKGROUND: Coxiella burnetii is a bacterium with extreme tenacity and contagiousness that is mainly transmitted by inhalation of contaminated aerosols. Nevertheless, a transmission by ticks is under discussion. We report a case of Q fever in an urban environment and far away from sheep breeding that caused a rare right-sided endocarditis. CASE PRESENTATION: A 55-year-old man who was in good health before the event developed a C. burnetii -endocarditis of the tricuspid valve. He had no contact with sheep and no recent travel in a rural or even endemic area. The infection originated in a strictly urban environment, and the patient's occupation as a cemetery gardener in Berlin, coupled with the close temporal and local exposure to wild boar, made a transmission by these animals a plausible hypothesis. The infection was confirmed by the German Reference Laboratory, and the patient recovered completely after treatment with doxycycline and hydrochlorquine. CONCLUSIONS: The specialities of this case report are the right-sided endocarditis and the transmission of C. burnetii in a metropolitan area without sheep contact. We think that this case should serve to increase awareness of the potential for Q fever infection even in non-rural areas.


Subject(s)
Coxiella burnetii , Endocarditis, Bacterial , Q Fever , Tricuspid Valve , Q Fever/transmission , Q Fever/microbiology , Q Fever/diagnosis , Q Fever/drug therapy , Male , Middle Aged , Humans , Tricuspid Valve/microbiology , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/transmission , Endocarditis, Bacterial/drug therapy , Coxiella burnetii/isolation & purification , Animals , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Sheep
12.
J Infect Dev Ctries ; 18(7): 1066-1073, 2024 Jul 29.
Article in English | MEDLINE | ID: mdl-39078792

ABSTRACT

INTRODUCTION: In our study, we aimed to evaluate the epidemiological features of brucellosis and the efficacy of different treatment options in patients with various organ involvements. METHODOLOGY: Patients diagnosed with brucellosis and treated in two different centers between 2009 and 2019 were retrospectively screened and evaluated regarding epidemiological and clinical features, laboratory findings, and treatment responses. RESULTS: The study included 297 complete-data patients (76% of rural patients were farmers). Farming (76%) and raw dairy (69%) were the main transmission methods. Most patients (98.6%) had positive tube agglutination tests. Ninety-two patients' blood and bodily fluid cultures grew Brucella spp. The incidence of leukopenia was 18.8%, thrombocytopenia 10.7%, anemia 34.3%, and pancytopenia 4.3%. Doxycycline and rifampicin were the major treatments, with streptomycin utilized in osteoarticular patients. Pregnant women with neurobrucellosis took ceftriaxone and trimethoprim-sulfamethoxazole. After one year, 7.1% of patients relapsed. Doxycycline + streptomycin and doxycycline + rifampicin had similar relapse rates (p = 0.799). The double- and triple-antibiotic groups had identical recurrence rates (p = 0.252). CONCLUSIONS: In uncomplicated brucellosis cases doxycycline + streptomycin and doxycycline + rifampicin treatments were equally effective. Again, there is no statistical difference in relapse development rates between double and triple combination treatments in uncomplicated brucellosis cases. Relapsed patients generally miss follow-ups, interrupt therapy, have osteoarticular involvement, and get short-term treatment. Patients with focused participation should be thoroughly checked at diagnosis and medicine, and treatment should be lengthy to prevent relapses.


Subject(s)
Anti-Bacterial Agents , Brucellosis , Doxycycline , Rifampin , Streptomycin , Humans , Brucellosis/drug therapy , Brucellosis/epidemiology , Turkey/epidemiology , Female , Adult , Male , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Middle Aged , Doxycycline/therapeutic use , Streptomycin/therapeutic use , Rifampin/therapeutic use , Young Adult , Adolescent , Aged , Pregnancy , Brucella/drug effects , Brucella/isolation & purification , Drug Therapy, Combination
13.
BMJ Case Rep ; 17(7)2024 Jul 18.
Article in English | MEDLINE | ID: mdl-39025797

ABSTRACT

Lymphogranuloma venereum (LGV) is a sexually transmitted infection caused by an invasive form of Chlamydia trachomatis, typically affecting the anogenital area with regional lymphatic involvement. Extragenital manifestations are rare but can occur, particularly if the bacterium is inoculated out of the genital tract. To our knowledge, only 13 cases of symptomatic neck LGV have been published so far in the medical literature. We describe a case of a young man living with HIV with bilateral, rapid-growing and painful neck swelling, whose definite diagnosis was challenging. The patient underwent extensive investigation, including repeated ultrasound-guided fine-needle aspirations, microbiological exams and histological characterisation. Genotyping revealed C. trachomatis L2 serovar, confirming LGV as a final diagnosis, affecting neck lymph nodes. Treatment with doxycycline combined with surgical drainage led to clinical resolution. This case emphasises the importance of a comprehensive testing strategy to identify LGV, especially in individuals reporting unprotected oral sex, with unexplained neck lymphadenitis.


Subject(s)
Chlamydia trachomatis , Doxycycline , HIV Infections , Lymphogranuloma Venereum , Neck , Humans , Male , Lymphogranuloma Venereum/diagnosis , Lymphogranuloma Venereum/complications , Lymphogranuloma Venereum/drug therapy , Neck/pathology , HIV Infections/complications , Doxycycline/therapeutic use , Chlamydia trachomatis/isolation & purification , Adult , Anti-Bacterial Agents/therapeutic use , Drainage , Lymph Nodes/pathology
14.
Diagn Microbiol Infect Dis ; 110(1): 116445, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39024931

ABSTRACT

Nontuberculous mycobacteria (NTM) are important opportunistic pathogens in humans, mostly affecting the lungs, and potentially causing progressive disease in individuals with underlying diseases. The prevalence of NTM infections is increasing worldwide. However, Mycobacterium iranicum (M. iranicum) infections are less common. Here we report a 65-year-old female who developed pneumonia caused by Mycobacterium iranicum, which was detected in bronchoalveolar lavage fluid (BALF) through metagenomic next-generation sequencing (mNGS). The patient was treated with moxifloxacin, doxycycline, and sulfamethoxazole/trimethoprim. Symptoms were relieved and lung abnormalities were shown to be partially absorbed on the follow-up chest computed tomography (CT) scans. As we know, this is the first case of Mycobacterium iranicum pulmonary infection identified by mNGS in BALF.


Subject(s)
Bronchoalveolar Lavage Fluid , High-Throughput Nucleotide Sequencing , Metagenomics , Mycobacterium Infections, Nontuberculous , Humans , Female , Aged , Bronchoalveolar Lavage Fluid/microbiology , Metagenomics/methods , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/diagnosis , Anti-Bacterial Agents/therapeutic use , Nontuberculous Mycobacteria/genetics , Nontuberculous Mycobacteria/isolation & purification , Nontuberculous Mycobacteria/drug effects , Tomography, X-Ray Computed , Moxifloxacin/therapeutic use , Doxycycline/therapeutic use
15.
Top Companion Anim Med ; 61: 100891, 2024.
Article in English | MEDLINE | ID: mdl-38972504

ABSTRACT

Treatment of Mycoplasma spp. pneumonia has rarely been described in domestic ferrets (Mustela putorius furo). A 10-month-old, 0.53 kg, female spayed domestic ferret was presented for oxygen-dependent, chronic dyspnea of one-month's duration. Physical examination findings included dyspnea, tachypnea, increased bronchovesicular sounds bilaterally, and an intermittent non-productive cough. Bloodwork abnormalities included a mild leukocytosis (8.6×103/µL), mild neutrophilia (4.0×103/µL), mild hypoalbuminemia (2.7 g/dL), mild hyperglobulinemia (3.3 g/dL), mild hyponatremia (147 mEq/L), and mild hypochloremia (111.4 mEq/L). Radiographs revealed a marked diffuse bronchial pattern with peribronchial cuffing, a mild main pulmonary artery bulge, distended caudal lobar pulmonary arteries, and decreased serosal detail within the abdomen. An echocardiogram revealed indications of moderate pulmonary hypertension and systolic anterior motion of the mitral valve. Polymerase chain reaction testing for Mycoplasma spp. was positive, and treatment was initiated with doxycycline (10 mg/kg PO q 12 h for 16 weeks), prednisolone (0.4 mg/kg PO q 12 h for 13 weeks, tapered to 0.2 mg/kg PO q 12 h for two weeks, then eventually increased to 0.7 mg/kg PO q 12 h until further notice), sildenafil (0.3 mg/kg PO q 24 h for 13 weeks), and oxygen supplementation via an oxygen cage for six weeks. On repeat echocardiogram eleven weeks after initiation of doxycycline therapy, the pulmonary hypertension had resolved. At follow up six months later, the ferret was stable on previously prescribed medications and did not require oxygen supplementation. Mycoplasma spp. and pulmonary hypertension should be considered in cases of respiratory distress in ferrets.


Subject(s)
Anti-Bacterial Agents , Ferrets , Hypertension, Pulmonary , Animals , Female , Hypertension, Pulmonary/veterinary , Anti-Bacterial Agents/therapeutic use , Pneumonia, Mycoplasma/veterinary , Pneumonia, Mycoplasma/drug therapy , Pneumonia, Mycoplasma/diagnosis , Doxycycline/therapeutic use , Prednisolone/therapeutic use , Sildenafil Citrate/therapeutic use
16.
Aust J Gen Pract ; 53(7): 499-503, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38959520

ABSTRACT

BACKGROUND AND OBJECTIVES: There were 82.4 million new gonorrhoea cases worldwide in 2020. Dual treatment with ceftriaxone or cefixime and azithromycin or doxycycline is currently recommended for gonorrhoea in Indonesia. However, reduced susceptibility and resistance to cephalosporins and azithromycin are increasing. We evaluated the susceptibility pattern of Neisseria gonorrhoeae to cefixime, ceftriaxone, azithromycin and doxycycline. METHOD: N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria. RESULTS: Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates. DISCUSSION: A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.


Subject(s)
Anti-Bacterial Agents , Azithromycin , Ceftriaxone , Doxycycline , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Humans , Indonesia , Neisseria gonorrhoeae/drug effects , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Gonorrhea/drug therapy , Male , Microbial Sensitivity Tests/methods , Azithromycin/therapeutic use , Doxycycline/therapeutic use , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Adult , Cefixime/therapeutic use , Cefixime/pharmacology , Primary Health Care/statistics & numerical data , Drug Resistance, Bacterial/drug effects , Drug Therapy, Combination/methods
17.
BMJ Case Rep ; 17(7)2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38960428

ABSTRACT

Scrub typhus, a prevalent tropical infection, may sometimes manifest with unusual complications. Here, we present the case of a young man who was admitted to our facility with a fever for the past 3 days and passage of dark-coloured urine since that morning. On investigation, we identified intravascular haemolytic anaemia. Through meticulous examination, a black necrotic lesion (eschar) was discovered on his right buttock, a pathognomonic sign of scrub typhus infection. Treatment was initiated with oral doxycycline 100 mg two times a day. Subsequently, diagnosis of scrub typhus was confirmed through positive results from scrub typhus IgM via ELISA and PCR analysis from the eschar tissue. The patient responded well to oral doxycycline and his symptoms resolved within the next few days. This case highlights severe intravascular haemolysis associated with scrub typhus infection.


Subject(s)
Anti-Bacterial Agents , Doxycycline , Scrub Typhus , Humans , Scrub Typhus/complications , Scrub Typhus/diagnosis , Scrub Typhus/drug therapy , Male , Doxycycline/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anemia, Hemolytic/etiology , Anemia, Hemolytic/diagnosis , Adult , Orientia tsutsugamushi/isolation & purification
18.
BMC Pulm Med ; 24(1): 340, 2024 Jul 15.
Article in English | MEDLINE | ID: mdl-39010032

ABSTRACT

BACKGROUND: We present an extremely rare manifestation of dirofilariasis in the pleural cavity. This is the first human pulmonary dirofilariasis reported in Lithuania; according to our knowledge, only two other patients were documented with this pathology in the world. CASE PRESENTATION: A 72-year-old woman was admitted to the hospital complaining of dyspnea, left-side chest pain, and a dry cough. She was a retiree living alone in the countryside without domestic pets (sometimes stray dogs appear) or a travel history. A complete blood count was within normal limits, with a CRP level of 16.8 mg/l and D-dimer concentration of 900 µg/l, which raised suspicion of pulmonary embolism. In chest computed tomography angiography, pulmonary embolism was excluded, and only left pleural effusion without abnormal lesions was confirmed. Left thoracocentesis was performed, and the pleural fluid was evaluated as an exudate with a predominance of eosinophils (59%), along with the presence of parasites. These parasites exhibited the morphology of Dirofilaria repens. Oral doxycycline (100 mg, twice daily) and albendazole (400 mg, twice daily) were prescribed for a 14-day course. A month later, there were no pathological findings on the chest X-ray, and the patient no longer had respiratory symptoms. However, the patient presented with an emerged, painful palpable right breastmass, where the rash was previously observed. Ultrasound imaging revealed a 1.5 × 2 cm nodule, which was surgically removed. Parasites consistent with Dirofilaria repens were suspected but not definitively identified. Pharmacological treatment for dirofilariasis was not further prescribed. CONCLUSIONS: This case encourages doctors to be more vigilant because the patient, who neither travelled nor kept any pets, contracted dirofilariasis. Diagnostic and treatment guidelines are lacking, necessitating further research. Treatment with doxycycline and albendazole yielded positive outcomes, suggesting potential efficacy for dirofilarial pleuritis.


Subject(s)
Albendazole , Dirofilariasis , Pleural Effusion , Dirofilariasis/diagnosis , Humans , Female , Aged , Pleural Effusion/etiology , Pleural Effusion/diagnosis , Pleural Effusion/diagnostic imaging , Pleural Effusion/parasitology , Animals , Albendazole/therapeutic use , Doxycycline/therapeutic use , Dirofilaria repens/isolation & purification
19.
Trends Parasitol ; 40(8): 667-669, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39060121

ABSTRACT

Can the antibiotic doxycycline unlock new possibilities in the fight against onchocerciasis-associated epilepsy (OAE)? Idro et al. explored this question by investigating for the first time doxycycline's impact on nodding syndrome (NS), a severe manifestation of OAE. Results reveal significant findings that may shape future treatment strategies.


Subject(s)
Doxycycline , Epilepsy , Onchocerciasis , Doxycycline/therapeutic use , Onchocerciasis/drug therapy , Onchocerciasis/complications , Humans , Epilepsy/drug therapy , Nodding Syndrome/drug therapy , Nodding Syndrome/complications , Anti-Bacterial Agents/therapeutic use
20.
Diagn Microbiol Infect Dis ; 110(2): 116435, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39032320

ABSTRACT

PURPOSE: Mycobacterium abscessus complex (MABC) infections are increasing worldwide. Furthermore, these infections have a low treatment success rate due to their resistance to many current antibiotics. This study aimed to determine the overall in vitro activity of the tetracyclines doxycycline (DOX), minocycline (MIN), and tigecycline (TGC) against MABC clinical isolates. PATIENTS AND METHODS: A systematic review of PubMed/MEDLINE, Web of Science, and Embase was conducted up to August 28, 2023. Studies applying the drug susceptibility testing standards of the Clinical and Laboratory Standards Institute were considered. A random effects model was used to assess the total in vitro resistance rates of the MABC clinical isolates to DOX, MIN, and TGC. The I2 and Cochran's Q statistics were employed to evaluate the origins of heterogeneity. All analyses were conducted using CMA V.3 software. RESULTS: Twenty-six publications (22, 12, and 11 studies on DOX, MIN, and TGC, respectively) were included. The pooled in vitro resistance rates of the MABC clinical isolates to DOX and MIN at the breakpoint of 8 µg/mL were 93.0 % (95 % CI, 89.2 %-95.5 %) and 87.2 % (95 % CI, 76.5 %-93.4 %), respectively. In the case of TGC, the breakpoints of 2, 4, and 8 µg/mL were associated with pooled resistance rates of 2.5 % (95 % CI, 0.5 %-11.6 %), 7.2 % (95 % CI, 4.0 %-12.5 %), and 16.8 % (95 % CI, 4.7 %-45.0 %), respectively. CONCLUSION: Among the three examined tetracyclines, MABC exhibited extremely high resistance rates to DOX and MIN, thereby limiting their use in treating MABC infections. Conversely, MABC showed an increased susceptibility rate to TGC, highlighting TGC administration as a viable treatment option for patients with MABC infections.


Subject(s)
Anti-Bacterial Agents , Doxycycline , Microbial Sensitivity Tests , Minocycline , Mycobacterium Infections, Nontuberculous , Mycobacterium abscessus , Tigecycline , Minocycline/pharmacology , Minocycline/analogs & derivatives , Tigecycline/pharmacology , Humans , Doxycycline/pharmacology , Doxycycline/therapeutic use , Mycobacterium abscessus/drug effects , Anti-Bacterial Agents/pharmacology , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/microbiology , Drug Resistance, Bacterial
SELECTION OF CITATIONS
SEARCH DETAIL